CONSYST-CRT II: Conduction System Pacing vs Biventricular Pacing in Systolic Dysfunction and Wide QRS: Mortality, Heart Failure Hospitalization or Cardiac Transplant

Sponsor
Hospital Clinic of Barcelona (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06105580
Collaborator
Institut d'Investigacions Biomèdiques August Pi i Sunyer (Other)
320
2
48

Study Details

Study Description

Brief Summary

Conduction system pacing vs biventricular resynchronization therapy in systolic dysfunction and wide QRS: mortality, heart failure hospitalization or cardiac transplant (CONSYST-CRT II trial).

Superiority trial that aims to study the composite endpoint consisting of all-cause mortality, cardiac transplant or heart failure hospitalization at 12-month follow-up.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Conduction system pacing
  • Procedure: Biventricular pacing
N/A

Detailed Description

To date, studies have shown that conduction system pacing could get similar clinical and echocardiographic responses to those obtained with biventricular therapy.

This study will randomize 320 patients to a strategy of biventricular pacing versus conduction system pacing.

CONSYST-CRT II study will analyze a clinical endpoint as primary endpoint and the following parameters in both groups: left ventricular ejection fraction, ventricular volumes, echocardiographic response (>=15% decrease in left ventricular end-systolic volume), NYHA functional class, heart failure hospitalization, all-cause mortality, cardiac transplant, QRS shortening, echocardiographic dyssynchrony (atrioventricular, interventricular, intraventricular) and global longitudinal strain.

As a secondary endpoint, baseline predictors of response to conduction system pacing and biventricular pacing according to cardiac magnetic ressonance and electrocardiographic imaging will be studied.

Clinical, electrocardiographic, echocardiographic follow-up will be performed during 12 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
320 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The first 130 patients have been recruited in the context of the CONSYST I study (ClinicalTrials.gov Identifier: NCT05187611).The first 130 patients have been recruited in the context of the CONSYST I study (ClinicalTrials.gov Identifier: NCT05187611).
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Conduction System Pacing vs Biventricular Resynchronization Therapy in Systolic Dysfunction and Wide QRS: Mortality, Heart Failure Hospitalization or Cardiac Transplant
Anticipated Study Start Date :
Oct 30, 2023
Anticipated Primary Completion Date :
Oct 30, 2027
Anticipated Study Completion Date :
Oct 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Conduction system pacing

Pacing the His-Purkinje system. Crossover to biventricular pacing allowed in case of failed conduction system pacing: failed His bundle pacing and failed Left bundle branch pacing (high thresholds (>3.5V / 1ms); no left bundle branch pacing criteria; no left bundle branch correction). Electrocardiographic optimization allowed in order to obtain the narrowest QRS.

Procedure: Conduction system pacing
Conduction system pacing implant as a Resynchronization therapy.

Active Comparator: Biventricular pacing

Pacing from the right ventricular and coronary sinus lead. Electrocardiographic optimization with fusion-optimized intervals (FOI). Crossover from biventricular pacing to conduction system pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation.

Procedure: Biventricular pacing
Biventricular pacing implant

Outcome Measures

Primary Outcome Measures

  1. Composite end-point: all-cause mortality, cardiac transplant or heart failure hospitalization. [1 year]

    Clinical follow-up at 12 months

Secondary Outcome Measures

  1. Change in left ventricular ejection fraction. [6 months; 1 year]

    Left ventricular ejection fraction measured with Simpson method with echocardiography.

  2. Change in left ventricular end-systolic volume. [6 months; 1 year]

    Left ventricular volumes measured with echocardiography. Simpson rule from 2- and 4-chamber apical views.

  3. Echocardiographic response. [6 months; 1 year]

    >=15% decrease in left ventricular end-systolic volume

  4. Change in NYHA functional class. [6 months; 1 year]

    NYHA functional class I, II, III, or IV

  5. QRS shortening. [Immediately after the intervention]

    QRS duration (milliseconds). QRS onset measured from fast deflection and from spike.

  6. Correction of septal flash. [15 days; 6 months; 1 year]

    Fast inward-outward movement of the interventricular septum in early systole. Using M-mode in parasternal short and long-axis views, septal flash was quantified (in millimeters) as the highest amplitude of the early inward motion measured from the resting position prior to the onset of septal contraction. The pair of septal flash measures (baseline and final) was obtained at the axis with the highest baseline SF.

  7. Correction of auriculoventricular dyssynchrony. [15 days; 6 months; 1 year]

    Left ventricular filling time. The left ventricular filling time was measured from the onset of the E-wave to the end of the A-wave, and the R-R interval was measured to calculate the percentage of filling time relative to the cardiac cycle (LV filling time/RR, %).

  8. Correction of interventricular dyssynchrony. [15 days; 6 months; 1 year]

    Quantified using pulsed Doppler and calculated as the time difference between QRS onset and the onset of the flow wave in the right and left outflow tracts.

  9. Change in global longitudinal strain (GLS). [15 days; 6 months; 1 year]

    Strain myocardial deformation of the left ventricle was quantified offline from 2-dimensional echocardiography using speckle tracking (2Dstrain, Echo Pac, version 202.41.0, GE Healthcare Milwaukee, WI). The long-axis cine images (2-, 3-, and 4-chamber views), were used to determine GLS.

  10. Description of baseline predictors of response to conduction system pacing and biventricular pacing. Cardiac fibrosis quantification. [Baseline (pre intervention).]

    Cardiac fibrosis quantification (grams of fibrosis)

  11. Description of baseline predictors of response to conduction system pacing and biventricular pacing with Electrocardiographic Imaging. Left ventricular activation time (LVAT), ms. [Baseline (pre intervention). And immediately after the intervention]

    Left ventricular activation time (LVAT), ms.

  12. Description of baseline predictors of response to conduction system pacing and biventricular pacing with Electrocardiographic Imaging. Ventricular electrical uncoupling (VEU). [Baseline (pre intervention). And immediately after the intervention]

    Ventricular electrical uncoupling (VEU) = mean left ventricular activation time - mean right ventricular activation time, ms

  13. Description of baseline predictors of response to conduction system pacing and biventricular pacing with Electrocardiographic Imaging. Left ventricular dyssynchrony index (LVDI). [Baseline (pre intervention). And immediately after the intervention]

    Left ventricular dyssynchrony index (LVDI): standard deviation of individual activations recorded from the left ventricle.

  14. Description of baseline predictors of response to conduction system pacing and biventricular pacing with Electrocardiographic Imaging. Conduction velocity (cm/s). [Baseline (pre intervention). And immediately after the intervention]

    Conduction velocity (cm/s).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient must indicate acceptance to participate in the study by signing an informed consent document.

  • Patient must be ≥ 18 years of age.

  • Left bundle branch block, QRS ≥130 and LVEF <=35%. No indication of stimulation for AV block.

  • Non-left bundle branch block, QRS ≥150 and LVEF <=35%.

  • Resynchronization therapy indication for ventricular dysfunction (LVEF <40%) and indication of cardiac pacing for AV block.

  • LVEF <=35% in NYHA class III or IV, atrial fibrillation and intrinsic QRS >=130 ms, provided a strategy to ensure biventricular capture is in place.

Exclusion Criteria:
  • Myocardial infarction, unstable angina or cardiac revascularization during the previous 3 months.

  • Pregnancy.

  • Participating currently in a clinical investigation that includes an active treatment.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Hospital Clinic of Barcelona
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer

Investigators

  • Principal Investigator: José Mª Tolosana, MD, PhD, Hospital Clínic de Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer
  • Principal Investigator: Margarida Pujol López, MD, Hospital Clínic de Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer
  • Study Chair: Lluís Mont, MD, PhD, Hospital Clínic de Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Josep Lluis Mont Girbau, Head of Arrhythmia Research., Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
NCT06105580
Other Study ID Numbers:
  • CONSYST-CRT II
First Posted:
Oct 27, 2023
Last Update Posted:
Oct 27, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Josep Lluis Mont Girbau, Head of Arrhythmia Research., Hospital Clinic of Barcelona
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 27, 2023